ZNF284L Inhibitors
Chemical inhibitors of ZNF284L can modulate its activity through various intracellular signaling pathways by targeting specific kinases responsible for its regulation. Staurosporine, a broad-spectrum protein kinase inhibitor, can inhibit multiple kinases that may phosphorylate ZNF284L, thus reducing its phosphorylation-dependent activity. Similarly, Bisindolylmaleimide I, a selective inhibitor of Protein Kinase C (PKC), can decrease PKC-mediated phosphorylation events that would otherwise activate ZNF284L. In the same vein, SP600125, as an inhibitor of c-Jun N-terminal kinase (JNK), can prevent the activation of ZNF284L that relies on JNK-mediated signaling events. LY294002, which targets phosphoinositide 3-kinase (PI3K), can inhibit PI3K/Akt pathway, potentially affecting ZNF284L functions that are PI3K-dependent. PD98059 and U0126, both inhibitors of mitogen-activated protein kinase kinase (MEK), can suppress the MEK/ERK pathway, potentially inhibiting any ERK-dependent regulation of ZNF284L.
Furthermore, SB203580, which inhibits p38 MAP kinase, can affect ZNF284L activity if it is regulated by stress-activated signaling pathways. Inhibition by PP2, targeting Src family tyrosine kinases, can reduce signaling events that activate ZNF284L. PD173074 acts on the fibroblast growth factor receptor (FGFR), and its inhibition can prevent the activation of downstream signaling that involves ZNF284L. Y-27632, a selective inhibitor of Rho-associated protein kinase (ROCK), can suppress the Rho/ROCK signaling pathway, which might be crucial for the regulation of ZNF284L. PD168393, an irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, can inhibit EGFR signaling cascades that include ZNF284L. Lastly, Chelerythrine, another potent inhibitor of PKC, can prevent PKC-dependent phosphorylation of ZNF284L, influencing its functional state. Each of these inhibitors can interfere with specific phosphorylation events and signaling pathways, leading to a reduction in ZNF284L's activity within the cellular context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can inhibit a wide range of kinases. Given that ZNF284L's function can be regulated by phosphorylation, staurosporine can inhibit the protein kinases that phosphorylate ZNF284L, thereby reducing its phosphorylation-dependent activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a selective inhibitor of Protein Kinase C (PKC). If ZNF284L's function is modulated by PKC signaling, this inhibitor can decrease PKC-mediated phosphorylation events that activate ZNF284L, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK pathway can regulate various transcription factors and proteins including zinc finger proteins. By inhibiting JNK, SP600125 may prevent the activation of ZNF284L that is dependent on JNK-mediated signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. If ZNF284L operates downstream of the PI3K/Akt pathway, LY294002 can inhibit this pathway, thus inhibiting the activation states or functions of ZNF284L which are PI3K-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). By inhibiting MEK, PD98059 can prevent the activation of ERK and thereby inhibit any function of ZNF284L that is dependent on the MEK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, which prevents the activation of MEK1/2. By inhibiting these kinases, U0126 can suppress the MEK/ERK pathway and consequently inhibit any functional role of ZNF284L that is regulated by this signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in stress responses and can regulate the activity of various proteins. Inhibition of this pathway by SB203580 could result in the inhibition of ZNF284L activity if ZNF284L is regulated by stress-activated signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases can influence a variety of signaling pathways that regulate protein function. By inhibiting Src kinases, PP2 can inhibit signaling events that activate ZNF284L, leading to the reduction in its functional activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a fibroblast growth factor receptor (FGFR) inhibitor. If ZNF284L is involved in FGFR signaling pathways, inhibition of FGFR by PD173074 can prevent the activation of downstream signaling that may be necessary for ZNF284L function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). If ZNF284L is regulated by Rho/ROCK signaling pathway, Y-27632 can inhibit this pathway, preventing any Rho/ROCK-dependent activation or regulation of ZNF284L. | ||||||